Alpelisib (Standard)
Alpelisib (Standard) is the analytical standard of Alpelisib. This product is intended for research and analytical applications. Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity[1][2][3].
Product Specifications
CAS Number
1217486-61-7
UNSPSC
12352100
Hazard Statement
H302, H315, H319, H335
Target
PI3K; Reference Standards
Related Pathways
Others; PI3K/Akt/mTOR
Field of Research
Cancer
Purity
99.86
Smiles
CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3
Molecular Formula
C19H22F3N5O2S
Molecular Weight
441.47
Precautions
H302, H315, H319, H335
References & Citations
[1]Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23 (13) :3741-8.|[2]Fritsch C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13 (5) :1117-29.|[3]Gobin B, et al. BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer. 2015 Feb 15;136 (4) :784-96.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, sealed storage, away from light and moisture
Scientific Category
Reference Standards
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740247-500 1x 500 µL
Transgelin / SM22-alpha (TAGLN/247), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
PKSM040425 100 µg
Recombinant Mouse FCRL1 Protein (aa 1-204, His Tag)
Sign In for Pricing
View Details 